Amylyx Pharmaceuticals, Inc. (AMLX) vs Precigen, Inc. (PGEN)
A side-by-side comparison of Amylyx Pharmaceuticals, Inc. and Precigen, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AMLX
Amylyx Pharmaceuticals, Inc.
$27.31HealthcareDelayed quote: Oct 6, 2026, 1:05 PM EDT
PGEN
Precigen, Inc.
$7.65HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
Total return — AMLX vs PGEN
growth of $100 · dividends reinvested · last 5yAMLX +53.7% (+9.0%/yr)PGEN +144.2% (+19.5%/yr)PGEN compounded faster over this window
AMLX PGEN
AMLX vs PGEN: by the numbers
- •AMLX is the larger company ($3.04B vs $2.73B market cap).
- •Both run net losses; AMLX's is the smaller (0.00% vs -183.98% net margin).
Metrics side by side
Valuation
| Metric | AMLX | PGEN |
|---|---|---|
| Forward P/E | N/A | 44.61 |
| P/S ratio | N/A | 31.80 |
| P/B ratio | 12.70 | 62.55 |
Profitability
| Metric | AMLX | PGEN |
|---|---|---|
| Gross margin | 0.00% | 37.05% |
| Operating margin | 0.00% | -1100.78% |
| Net margin | 0.00% | -183.98% |
| ROE | -63.59% | -361.91% |
| ROIC | -66.60% | -28.02% |
Growth (annualized)
| Metric | AMLX | PGEN |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -21.26% |
| Total return CAGR (5Y) | N/A | 8.79% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.